<!DOCTYPE html>
<html lang="en" data-arca>
<head>
  <meta charset="UTF-8">
  <meta name="viewport" content="width=device-width, initial-scale=1.0">
  <title>Hematology Solutions — ArcaScience | AI-Driven Benefit-Risk Analysis</title>
  <meta name="description" content="ArcaScience's AI-driven benefit-risk analysis platform for Hematology. 7B+ records covering cell and gene therapies, anticoagulants, rare blood disorder treatments, and specialized small-population BRA methodologies.">

  <!-- Fonts: self-hosted for performance -->
  <link rel="preload" href="/fonts/Inter-Variable.woff2" as="font" type="font/woff2" crossorigin>
  <link rel="preload" href="/fonts/Literata-Variable.woff2" as="font" type="font/woff2" crossorigin>

  <!-- Global CSS (from build) -->
  <link rel="stylesheet" href="/dist/arcascience-global.min.css">

  <!-- Reduced motion detection before paint -->
  <script>
    (function(){
      if(window.matchMedia&&window.matchMedia('(prefers-reduced-motion: reduce)').matches){
        document.documentElement.classList.add('reduced-motion');
      }
    })();
  </script>
</head>
<body>

  <!-- SCROLL PROGRESS BAR -->
  <div data-scroll-progress></div>

  <!-- NAVIGATION -->
  <nav class="arca-nav" data-nav="sticky" role="navigation" aria-label="Main navigation">
    <div style="max-width: var(--content-max-width); margin: 0 auto; padding: 0 24px; display: flex; align-items: center; justify-content: space-between; height: 100%;">

      <!-- Logo -->
      <a href="/" aria-label="ArcaScience home">
        <img src="/images/arcascience-logo.svg" alt="ArcaScience" height="32">
      </a>

      <!-- Nav Links -->
      <div style="display: flex; align-items: center; gap: 32px;">
        <a href="/" class="arca-nav-link">Home</a>

        <!-- Platform dropdown -->
        <div style="position: relative;">
          <a href="/platform-overview" class="arca-nav-link">Platform</a>
        </div>

        <!-- Solutions dropdown — ACTIVE -->
        <div style="position: relative;">
          <a href="/solution-therapeutic-area" class="arca-nav-link is-active">Solutions</a>
        </div>

        <a href="/science-methodology" class="arca-nav-link">Science</a>
        <a href="/evidence-case-studies-hub" class="arca-nav-link">Evidence</a>
        <a href="/about" class="arca-nav-link">Company</a>
        <a href="/resources" class="arca-nav-link">Resources</a>
      </div>

      <!-- Header CTA -->
      <a href="/contact" class="arca-btn-primary" style="height: 40px; padding: 8px 24px; font-size: 0.875rem;">
        Talk to a Scientist
      </a>
    </div>
  </nav>

  <!-- Spacer for fixed nav -->
  <div style="height: var(--nav-height);"></div>

  <main role="main">

    <!-- SECTION 1: BREADCRUMB + DARK HERO -->
    <section class="arca-bg-blue-900" style="padding: var(--space-8) 0 var(--space-9);" data-animate>
      <div style="max-width: var(--content-max-width); margin: 0 auto; padding: 0 24px;">

        <!-- Breadcrumb -->
        <nav aria-label="Breadcrumb" style="margin-bottom: var(--space-5);">
          <ol style="list-style: none; padding: 0; margin: 0; display: flex; align-items: center; gap: 8px; font-size: 0.75rem;">
            <li><a href="/" style="color: rgba(255,255,255,0.65); text-decoration: none;">Home</a></li>
            <li style="color: rgba(255,255,255,0.4);">/</li>
            <li><a href="/solution-therapeutic-area" style="color: rgba(255,255,255,0.65); text-decoration: none;">Solutions</a></li>
            <li style="color: rgba(255,255,255,0.4);">/</li>
            <li><a href="/solution-therapeutic-area" style="color: rgba(255,255,255,0.65); text-decoration: none;">Therapeutic Areas</a></li>
            <li style="color: rgba(255,255,255,0.4);">/</li>
            <li style="color: var(--white);">Hematology</li>
          </ol>
        </nav>

        <div style="max-width: 820px;">
          <p class="arca-label arca-text-blue-400" style="margin-bottom: var(--space-3);">
            Therapeutic Area Solutions
          </p>
          <h1 class="arca-display-lg arca-text-white" style="margin-bottom: var(--space-5);">
            Hematology Benefit-Risk Analysis
          </h1>
          <p class="arca-body-lg" style="color: rgba(255,255,255,0.85); max-width: 680px; margin-bottom: var(--space-7);">
            Specialized BRA for hematology therapies — cell and gene therapies, anticoagulants, hemophilia treatments, and rare blood disorder interventions requiring small-population statistical methodologies and long-term safety follow-up.
          </p>
          <a href="/contact" class="arca-btn-primary-inverted">
            Request Hematology Briefing
          </a>
        </div>

      </div>
    </section>

    <!-- SECTION 2: DATA COVERAGE STATS -->
    <section class="arca-credibility-bar" data-animate>
      <div style="max-width: var(--content-max-width); margin: 0 auto; padding: 0 24px;">
        <div style="display: grid; grid-template-columns: repeat(4, 1fr); gap: 32px; text-align: center;">

          <div class="arca-credibility-metric">
            <span class="arca-stat-lg" data-countup="7000000000" data-countup-suffix="+">0</span>
            <p class="arca-caption">Hematology-specific safety records</p>
          </div>

          <div class="arca-credibility-metric">
            <span class="arca-stat-lg" data-countup="4800" data-countup-suffix="+">0</span>
            <p class="arca-caption">Hematology clinical trials analyzed</p>
          </div>

          <div class="arca-credibility-metric">
            <span class="arca-stat-lg" data-countup="12" data-countup-suffix="+">0</span>
            <p class="arca-caption">Gene/cell therapy submissions supported</p>
          </div>

          <div class="arca-credibility-metric">
            <span class="arca-stat-lg" data-countup="15" data-countup-suffix=" yr">0</span>
            <p class="arca-caption">Long-term follow-up data coverage</p>
          </div>

        </div>
      </div>
    </section>

    <!-- SECTION 3: TA-SPECIFIC CHALLENGE SECTION -->
    <section style="padding: var(--space-9) 0;" data-animate>
      <div style="max-width: var(--content-max-width); margin: 0 auto; padding: 0 24px;">
        <div style="max-width: 720px; margin: 0 auto 48px; text-align: center;">
          <p class="arca-section-label">Unique Challenges</p>
          <h2 class="arca-display-sm" style="margin-bottom: var(--space-5);">
            Why Hematology BRA Is Different
          </h2>
          <p class="arca-body-lg arca-text-grey-600">
            Hematology therapies span from well-established anticoagulants to cutting-edge gene therapies, each presenting distinct benefit-risk challenges driven by bleeding/thrombotic event balancing, rare disease populations, and novel safety profiles requiring decades of follow-up.
          </p>
        </div>

        <!-- 3 TA-specific challenge cards -->
        <div style="display: grid; grid-template-columns: repeat(3, 1fr); gap: 24px;">

          <div class="arca-card" data-animate>
            <h3 class="arca-heading-3" style="margin-bottom: var(--space-3);">Bleeding & Thrombotic Event Balancing</h3>
            <p class="arca-body-sm arca-text-grey-600">
              Anticoagulants and antiplatelet therapies require continuous benefit-risk optimization between preventing thrombotic events and minimizing hemorrhagic complications. DOACs, heparins, and novel factor XI inhibitors each have distinct bleeding profiles. BRA must incorporate time-in-therapeutic-range analysis, ISTH bleeding classification, and patient-specific risk scoring (CHA2DS2-VASc, HAS-BLED) to generate clinically meaningful benefit-risk profiles.
            </p>
          </div>

          <div class="arca-card" data-animate>
            <h3 class="arca-heading-3" style="margin-bottom: var(--space-3);">Long-Term Gene Therapy Safety</h3>
            <p class="arca-body-sm arca-text-grey-600">
              Gene therapies for hemophilia A/B, sickle cell disease, and beta-thalassemia require 15-year post-authorization safety follow-up to monitor for insertional mutagenesis, vector integration-site oncogenesis, and durability of transgene expression. The challenge is conducting meaningful benefit-risk assessment with limited long-term data and evolving understanding of genome editing off-target effects from CRISPR-based and base-editing therapies.
            </p>
          </div>

          <div class="arca-card" data-animate>
            <h3 class="arca-heading-3" style="margin-bottom: var(--space-3);">Small-Population BRA Methodology</h3>
            <p class="arca-body-sm arca-text-grey-600">
              Rare hematologic conditions — thrombotic thrombocytopenic purpura (TTP), paroxysmal nocturnal hemoglobinuria (PNH), aplastic anemia — have patient populations too small for traditional frequentist statistical approaches. BRA requires Bayesian methods, external control arms from natural history studies, and registry data augmentation to generate regulatory-grade benefit-risk assessments from trials enrolling fewer than 100 patients.
            </p>
          </div>

        </div>
      </div>
    </section>

    <!-- SECTION 4: PLATFORM CAPABILITIES FOR THIS TA -->
    <section class="arca-bg-grey-50" style="padding: var(--space-9) 0;" data-animate>
      <div style="max-width: var(--content-max-width); margin: 0 auto; padding: 0 24px;">
        <div style="text-align: center; margin-bottom: var(--space-8);">
          <p class="arca-section-label">Platform Capabilities</p>
          <h2 class="arca-display-sm" style="margin-bottom: var(--space-4);">
            How ArcaScience Addresses Hematology BRA Challenges
          </h2>
          <p class="arca-body-lg arca-text-grey-600" style="max-width: 680px; margin: 0 auto;">
            Our three integrated modules — Data Intelligence, Decision Intelligence, and Automated Outputs — are configured for Hematology-specific benefit-risk assessment workflows.
          </p>
        </div>

        <!-- 3 module cards with colored tops -->
        <div style="display: grid; grid-template-columns: repeat(3, 1fr); gap: 24px;">

          <!-- Module 1: Data Intelligence (teal) -->
          <div class="arca-card arca-card-colored-top is-data" data-animate>
            <span class="arca-module-tag is-data">Data Intelligence</span>
            <h3 class="arca-heading-2" style="margin: var(--space-4) 0 var(--space-3);">
              Hematology Data Coverage
            </h3>
            <p class="arca-body-sm arca-text-grey-600" style="margin-bottom: var(--space-5);">
              Comprehensive hematology data from 4,800+ clinical trials, 7B+ adverse event records, rare disease registries (INALC, WBDR, PNH Registry), and gene therapy long-term follow-up databases. Includes ISTH-classified bleeding event data, anticoagulant therapeutic range databases, hemophilia joint outcome scores, and sickle cell crisis frequency registries with MedDRA coding optimized for hematologic safety signals.
            </p>
            <a href="/platform-data-intelligence" class="arca-btn-tertiary">
              Explore Data Engine <span class="arca-arrow">&rarr;</span>
            </a>
          </div>

          <!-- Module 2: Decision Intelligence (indigo) -->
          <div class="arca-card arca-card-colored-top is-analytics" data-animate>
            <span class="arca-module-tag is-analytics">Decision Intelligence</span>
            <h3 class="arca-heading-2" style="margin: var(--space-4) 0 var(--space-3);">
              TA-Specific AI Models
            </h3>
            <p class="arca-body-sm arca-text-grey-600" style="margin-bottom: var(--space-5);">
              6 AI models trained specifically on hematology safety and efficacy patterns, including bleeding event prediction and classification, thrombotic risk scoring, gene therapy durability modeling, and small-population Bayesian BRA. Specialized algorithms for CAR-T cytokine release syndrome grading, ICANS neurotoxicity detection, and anticoagulant reversal agent effectiveness analysis.
            </p>
            <a href="/platform-ai-models" class="arca-btn-tertiary">
              Explore AI Models <span class="arca-arrow">&rarr;</span>
            </a>
          </div>

          <!-- Module 3: Automated Outputs (green) -->
          <div class="arca-card arca-card-colored-top is-output" data-animate>
            <span class="arca-module-tag is-output">Automated Outputs</span>
            <h3 class="arca-heading-2" style="margin: var(--space-4) 0 var(--space-3);">
              Hematology Regulatory Outputs
            </h3>
            <p class="arca-body-sm arca-text-grey-600" style="margin-bottom: var(--space-5);">
              Submission-ready bleeding event analyses, gene therapy long-term follow-up reports, PSUR/PBRER with hematology-specific safety sections, and ATMP-specific Risk Management Plans. Outputs formatted for FDA CBER/CDER, EMA CAT (Committee for Advanced Therapies), and PMDA requirements, including 15-year gene therapy follow-up report templates and rare disease registry data integration summaries.
            </p>
            <a href="/platform-outputs" class="arca-btn-tertiary">
              Explore Outputs <span class="arca-arrow">&rarr;</span>
            </a>
          </div>

        </div>
      </div>
    </section>

    <!-- SECTION 5: ADVERSE EVENT LANDSCAPE -->
    <section style="padding: var(--space-9) 0;" data-animate>
      <div style="max-width: var(--content-max-width); margin: 0 auto; padding: 0 24px;">
        <div style="max-width: 720px; margin: 0 auto 48px; text-align: center;">
          <p class="arca-section-label">Safety Intelligence</p>
          <h2 class="arca-display-sm" style="margin-bottom: var(--space-5);">
            Hematology Adverse Event Landscape
          </h2>
          <p class="arca-body-lg arca-text-grey-600">
            Key safety signal categories tracked across hematology development programs, with AI-powered detection for both established therapeutic classes and novel cell and gene therapy modalities.
          </p>
        </div>

        <!-- AE category grid -->
        <div style="display: grid; grid-template-columns: repeat(3, 1fr); gap: 16px;">

          <div class="arca-card" style="padding: var(--space-5); border-left: 3px solid var(--indigo-500);" data-animate>
            <h4 class="arca-heading-4" style="margin-bottom: var(--space-2); color: var(--indigo-600);">Cytokine Release Syndrome</h4>
            <p class="arca-body-sm arca-text-grey-600">
              CRS grading (ASTCT consensus) in CAR-T cell therapy — ranging from mild fever to life-threatening capillary leak and multi-organ failure requiring tocilizumab intervention and ICU-level monitoring protocols.
            </p>
          </div>

          <div class="arca-card" style="padding: var(--space-5); border-left: 3px solid var(--indigo-500);" data-animate>
            <h4 class="arca-heading-4" style="margin-bottom: var(--space-2); color: var(--indigo-600);">ICANS Neurotoxicity</h4>
            <p class="arca-body-sm arca-text-grey-600">
              Immune effector cell-associated neurotoxicity syndrome — encephalopathy, seizures, cerebral edema — a CAR-T-specific safety signal requiring ICE score monitoring and specialized neurologic assessment protocols.
            </p>
          </div>

          <div class="arca-card" style="padding: var(--space-5); border-left: 3px solid var(--indigo-500);" data-animate>
            <h4 class="arca-heading-4" style="margin-bottom: var(--space-2); color: var(--indigo-600);">Major Bleeding Events</h4>
            <p class="arca-body-sm arca-text-grey-600">
              Intracranial hemorrhage, GI bleeding, and fatal bleeds with anticoagulants — classified per ISTH criteria and requiring continuous benefit-risk balancing against thromboembolic event prevention.
            </p>
          </div>

          <div class="arca-card" style="padding: var(--space-5); border-left: 3px solid var(--indigo-500);" data-animate>
            <h4 class="arca-heading-4" style="margin-bottom: var(--space-2); color: var(--indigo-600);">Insertional Oncogenesis</h4>
            <p class="arca-body-sm arca-text-grey-600">
              Vector integration near proto-oncogenes in gene therapy — the critical long-term safety signal requiring 15-year monitoring, integration site analysis, and clonal expansion surveillance for lentiviral and AAV-based therapies.
            </p>
          </div>

          <div class="arca-card" style="padding: var(--space-5); border-left: 3px solid var(--indigo-500);" data-animate>
            <h4 class="arca-heading-4" style="margin-bottom: var(--space-2); color: var(--indigo-600);">Inhibitor Development</h4>
            <p class="arca-body-sm arca-text-grey-600">
              Anti-drug antibodies (inhibitors) against factor VIII/IX in hemophilia patients — occurring in up to 30% of severe hemophilia A patients and fundamentally altering the benefit-risk profile of replacement therapies.
            </p>
          </div>

          <div class="arca-card" style="padding: var(--space-5); border-left: 3px solid var(--indigo-500);" data-animate>
            <h4 class="arca-heading-4" style="margin-bottom: var(--space-2); color: var(--indigo-600);">Veno-Occlusive Disease</h4>
            <p class="arca-body-sm arca-text-grey-600">
              Hepatic VOD/SOS following conditioning regimens for stem cell transplant and CAR-T therapy — a serious complication requiring early detection biomarkers and defibrotide intervention monitoring.
            </p>
          </div>

        </div>

        <!-- Link to data coverage -->
        <div style="text-align: center; margin-top: var(--space-7);">
          <a href="/platform-data-intelligence" class="arca-btn-tertiary">
            See Full Hematology Data Coverage <span class="arca-arrow">&rarr;</span>
          </a>
        </div>
      </div>
    </section>

    <!-- SECTION 6: CASE STUDY EXCERPT -->
    <section class="arca-bg-blue-50" style="padding: var(--space-9) 0;" data-animate>
      <div style="max-width: var(--content-max-width); margin: 0 auto; padding: 0 24px;">
        <div style="display: grid; grid-template-columns: 1fr 1fr; gap: 64px; align-items: center;">

          <!-- Left: Case study content -->
          <div>
            <p class="arca-section-label">Case Study — Hematology</p>
            <h2 class="arca-heading-1" style="margin-bottom: var(--space-5);">
              CAR-T Cell Therapy — Cytokine Release Syndrome Monitoring
            </h2>

            <div style="margin-bottom: var(--space-5);">
              <h3 class="arca-heading-4" style="margin-bottom: var(--space-2); color: var(--indigo-600);">Challenge</h3>
              <p class="arca-body-sm arca-text-grey-600">
                A cell therapy developer needed to establish comprehensive CRS and ICANS monitoring across their CAR-T platform targeting B-cell malignancies. Post-approval REMS commitments required real-time safety monitoring at 120+ certified treatment centers, standardized CRS grading per ASTCT consensus criteria, and automated FAERS reporting for Grade 3+ events — while simultaneously building the long-term safety database for secondary malignancy monitoring mandated by FDA.
              </p>
            </div>

            <div style="margin-bottom: var(--space-5);">
              <h3 class="arca-heading-4" style="margin-bottom: var(--space-2); color: var(--indigo-600);">Approach</h3>
              <p class="arca-body-sm arca-text-grey-600">
                ArcaScience deployed hematology-specific AI models for CRS severity prediction from early cytokine biomarkers (IL-6, ferritin, CRP), automated ASTCT grading classification, and real-time REMS compliance monitoring across treatment sites. Bayesian signal detection for rare events (secondary T-cell lymphomas) was implemented with integration of CIBMTR registry data as an external comparator for expected malignancy rates post-lymphodepletion.
              </p>
            </div>

            <div style="display: grid; grid-template-columns: repeat(2, 1fr); gap: 24px; margin-bottom: var(--space-6);">
              <div>
                <span class="arca-stat-sm" style="color: var(--indigo-600);" data-countup="24" data-countup-suffix="hr">0</span>
                <p class="arca-caption arca-text-grey-600">Earlier CRS severity prediction</p>
              </div>
              <div>
                <span class="arca-stat-sm" style="color: var(--indigo-600);" data-countup="120" data-countup-suffix="+">0</span>
                <p class="arca-caption arca-text-grey-600">Treatment centers monitored</p>
              </div>
              <div>
                <span class="arca-stat-sm" style="color: var(--indigo-600);" data-countup="50" data-countup-suffix="%">0</span>
                <p class="arca-caption arca-text-grey-600">Reduction in REMS reporting burden</p>
              </div>
            </div>

            <a href="/evidence-case-studies-hub" class="arca-btn-tertiary">
              Read Full Case Study <span class="arca-arrow">&rarr;</span>
            </a>
          </div>

          <!-- Right: Testimonial -->
          <div class="arca-testimonial" style="text-align: left;">
            <div class="arca-testimonial-quote" style="padding-left: 24px; border-left: 3px solid var(--blue-400);">
              The ability to predict CRS severity 24 hours earlier using ArcaScience's cytokine biomarker models has fundamentally changed our approach to CAR-T safety management. We can now intervene proactively rather than reactively, improving patient outcomes while meeting our REMS obligations efficiently.
            </div>
            <div class="arca-testimonial-attribution" style="margin-top: var(--space-5);">
              <p class="arca-body-md" style="font-weight: 600;">Dr. Michael Torres</p>
              <p class="arca-body-sm arca-text-grey-600">Chief Medical Officer, Cell Therapy Developer</p>
            </div>
          </div>

        </div>
      </div>
    </section>

    <!-- SECTION 7: REGULATORY CONTEXT -->
    <section style="padding: var(--space-9) 0;" data-animate>
      <div style="max-width: var(--content-max-width); margin: 0 auto; padding: 0 24px;">
        <div style="max-width: 720px; margin: 0 auto 48px; text-align: center;">
          <p class="arca-section-label">Regulatory Intelligence</p>
          <h2 class="arca-display-sm" style="margin-bottom: var(--space-5);">
            Hematology Regulatory Context
          </h2>
          <p class="arca-body-lg arca-text-grey-600">
            Key regulatory considerations and guidance specific to hematology benefit-risk assessment, including cell/gene therapy requirements, for FDA, EMA, and PMDA submissions.
          </p>
        </div>

        <!-- Accordion for regulatory guidance -->
        <div style="max-width: 820px; margin: 0 auto;">

          <div class="arca-accordion" data-accordion>

            <!-- Accordion item 1 -->
            <div class="arca-accordion-item" style="border-bottom: 1px solid var(--grey-200);">
              <button class="arca-accordion-header" style="width: 100%; text-align: left; padding: var(--space-5) 0; display: flex; justify-content: space-between; align-items: center; background: none; border: none; cursor: pointer;">
                <h3 class="arca-heading-3">FDA Gene Therapy & Cell Therapy Guidance</h3>
                <span class="arca-accordion-icon" style="color: var(--grey-500); font-size: 1.25rem;">+</span>
              </button>
              <div class="arca-accordion-content" style="padding: 0 0 var(--space-5); display: none;">
                <p class="arca-body-sm arca-text-grey-600">
                  FDA's CBER has issued comprehensive guidance for gene therapy products including "Long Term Follow-Up After Administration of a Human Gene Therapy Product" (2020, updated 2024) mandating 15-year post-approval safety monitoring for integrating vectors and 5 years for non-integrating vectors. For CAR-T products, FDA requires REMS programs with Elements to Assure Safe Use (ETASU) including certified treatment center requirements and mandatory CRS/ICANS monitoring protocols.
                </p>
                <p class="arca-body-sm arca-text-grey-600" style="margin-top: var(--space-3);">
                  <strong>Key requirements:</strong> Integration site analysis for gene therapy long-term follow-up, standardized CRS/ICANS grading per ASTCT criteria, secondary malignancy monitoring (including T-cell lymphomas for CAR-T), vector shedding studies, and Regenerative Medicine Advanced Therapy (RMAT) designation benefit-risk frameworks for accelerated approval pathways.
                </p>
              </div>
            </div>

            <!-- Accordion item 2 -->
            <div class="arca-accordion-item" style="border-bottom: 1px solid var(--grey-200);">
              <button class="arca-accordion-header" style="width: 100%; text-align: left; padding: var(--space-5) 0; display: flex; justify-content: space-between; align-items: center; background: none; border: none; cursor: pointer;">
                <h3 class="arca-heading-3">EMA ATMP Requirements</h3>
                <span class="arca-accordion-icon" style="color: var(--grey-500); font-size: 1.25rem;">+</span>
              </button>
              <div class="arca-accordion-content" style="padding: 0 0 var(--space-5); display: none;">
                <p class="arca-body-sm arca-text-grey-600">
                  EMA's Committee for Advanced Therapies (CAT) evaluates all Advanced Therapy Medicinal Products (ATMPs) including gene therapies, somatic cell therapies, and tissue-engineered products under Regulation (EC) No 1394/2007. CAT requires comprehensive risk management plans with ATMP-specific safety concerns, long-term efficacy and safety follow-up studies, and patient registries for rare hematologic conditions. PRIME (PRIority MEdicines) designation provides enhanced regulatory support for promising hematology ATMPs.
                </p>
                <p class="arca-body-sm arca-text-grey-600" style="margin-top: var(--space-3);">
                  <strong>Key focus areas:</strong> ATMP-specific PSUR requirements, post-authorization efficacy studies (PAES) for conditional approvals, EU ATMP registry integration, hospital exemption provisions for patient-specific cell therapies, and HTA-aligned outcomes data for ATMP reimbursement negotiations given high treatment costs.
                </p>
              </div>
            </div>

            <!-- Accordion item 3 -->
            <div class="arca-accordion-item" style="border-bottom: 1px solid var(--grey-200);">
              <button class="arca-accordion-header" style="width: 100%; text-align: left; padding: var(--space-5) 0; display: flex; justify-content: space-between; align-items: center; background: none; border: none; cursor: pointer;">
                <h3 class="arca-heading-3">PMDA Guidance for Hematology Products</h3>
                <span class="arca-accordion-icon" style="color: var(--grey-500); font-size: 1.25rem;">+</span>
              </button>
              <div class="arca-accordion-content" style="padding: 0 0 var(--space-5); display: none;">
                <p class="arca-body-sm arca-text-grey-600">
                  Japan's PMDA regulates regenerative medicine products under the Act on the Safety of Regenerative Medicine and the Pharmaceuticals and Medical Devices Act (PMD Act). PMDA's conditional and time-limited approval pathway for regenerative products requires periodic re-evaluation of benefit-risk with real-world effectiveness data. For hematology gene therapies, PMDA requires Japanese patient safety data with attention to ethnic factors affecting vector immunogenicity and transgene expression durability.
                </p>
                <p class="arca-body-sm arca-text-grey-600" style="margin-top: var(--space-3);">
                  <strong>Submission requirements:</strong> Japanese bridging studies for cell/gene therapies, mandatory all-case post-marketing surveillance, J-RMP with gene therapy-specific risk minimization measures, alignment with SAKIGAKE designation for breakthrough regenerative medicines, and post-marketing re-examination data within 7 years for conditional approvals.
                </p>
              </div>
            </div>

            <!-- Accordion item 4 -->
            <div class="arca-accordion-item">
              <button class="arca-accordion-header" style="width: 100%; text-align: left; padding: var(--space-5) 0; display: flex; justify-content: space-between; align-items: center; background: none; border: none; cursor: pointer;">
                <h3 class="arca-heading-3">Post-Marketing Requirements for Hematology Therapies</h3>
                <span class="arca-accordion-icon" style="color: var(--grey-500); font-size: 1.25rem;">+</span>
              </button>
              <div class="arca-accordion-content" style="padding: 0 0 var(--space-5); display: none;">
                <p class="arca-body-sm arca-text-grey-600">
                  Regulatory authorities globally require enhanced post-marketing surveillance for hematology therapies, particularly cell and gene therapies with mandated long-term follow-up. ArcaScience automates PSUR/PBRER generation, gene therapy 15-year follow-up reports, REMS compliance monitoring, and rare disease registry data integration aligned with ICH E2C(R2), EU GVP Module VIII, and FDA LTFU guidance. Specialized hematology safety signal libraries cover CRS/ICANS for CAR-T, bleeding/thrombotic events for anticoagulants, inhibitor development for factor replacement therapies, and insertional oncogenesis for gene therapies.
                </p>
              </div>
            </div>

          </div>

          <div style="text-align: center; margin-top: var(--space-7);">
            <a href="/resources" class="arca-btn-tertiary">
              View All Hematology Regulatory Updates <span class="arca-arrow">&rarr;</span>
            </a>
          </div>

        </div>
      </div>
    </section>

    <!-- SECTION 8: RELATED RESOURCES -->
    <section class="arca-bg-grey-50" style="padding: var(--space-9) 0;" data-animate>
      <div style="max-width: var(--content-max-width); margin: 0 auto; padding: 0 24px;">
        <div style="text-align: center; margin-bottom: var(--space-8);">
          <p class="arca-section-label">Resources</p>
          <h2 class="arca-display-sm">Related Hematology Resources</h2>
        </div>

        <div style="display: grid; grid-template-columns: repeat(3, 1fr); gap: 24px;">

          <!-- Resource 1: Whitepaper -->
          <a href="/resources-whitepapers" class="arca-card" style="text-decoration: none; color: inherit; display: flex; flex-direction: column; height: 100%;" data-animate>
            <div style="padding: var(--space-2) var(--space-3); background: var(--blue-50); border-radius: 4px; margin-bottom: var(--space-4); display: inline-block; align-self: flex-start;">
              <span class="arca-label" style="color: var(--blue-600); font-size: 0.625rem; text-transform: uppercase; letter-spacing: 0.05em;">Whitepaper</span>
            </div>
            <h3 class="arca-heading-3" style="margin-bottom: var(--space-3);">Gene Therapy Long-Term Safety Monitoring: AI-Driven Approaches</h3>
            <p class="arca-body-sm arca-text-grey-600" style="margin-bottom: var(--space-4); flex-grow: 1;">
              Methodology for 15-year gene therapy follow-up monitoring, including integration site analysis automation, clonal expansion detection, and regulatory reporting across FDA, EMA, and PMDA requirements.
            </p>
            <span class="arca-btn-tertiary" style="display: inline-flex; align-self: flex-start;">
              Download Whitepaper <span class="arca-arrow">&rarr;</span>
            </span>
          </a>

          <!-- Resource 2: Blog Post -->
          <a href="/resources" class="arca-card" style="text-decoration: none; color: inherit; display: flex; flex-direction: column; height: 100%;" data-animate>
            <div style="padding: var(--space-2) var(--space-3); background: var(--indigo-50); border-radius: 4px; margin-bottom: var(--space-4); display: inline-block; align-self: flex-start;">
              <span class="arca-label" style="color: var(--indigo-600); font-size: 0.625rem; text-transform: uppercase; letter-spacing: 0.05em;">Insight</span>
            </div>
            <h3 class="arca-heading-3" style="margin-bottom: var(--space-3);">CAR-T Safety Landscape 2026: Secondary Malignancy Signal Analysis</h3>
            <p class="arca-body-sm arca-text-grey-600" style="margin-bottom: var(--space-4); flex-grow: 1;">
              Analysis of emerging T-cell lymphoma signals in CAR-T recipients, regulatory responses from FDA and EMA, and implications for benefit-risk assessment in hematologic malignancies.
            </p>
            <span class="arca-btn-tertiary" style="display: inline-flex; align-self: flex-start;">
              Read Article <span class="arca-arrow">&rarr;</span>
            </span>
          </a>

          <!-- Resource 3: Webinar -->
          <a href="/resources-webinars" class="arca-card" style="text-decoration: none; color: inherit; display: flex; flex-direction: column; height: 100%;" data-animate>
            <div style="padding: var(--space-2) var(--space-3); background: var(--green-50); border-radius: 4px; margin-bottom: var(--space-4); display: inline-block; align-self: flex-start;">
              <span class="arca-label" style="color: var(--green-600); font-size: 0.625rem; text-transform: uppercase; letter-spacing: 0.05em;">Webinar</span>
            </div>
            <h3 class="arca-heading-3" style="margin-bottom: var(--space-3);">Small-Population BRA in Rare Hematologic Conditions</h3>
            <p class="arca-body-sm arca-text-grey-600" style="margin-bottom: var(--space-4); flex-grow: 1;">
              On-demand webinar covering Bayesian BRA methods for rare blood disorders, external control arm construction, and regulatory acceptance of small-sample benefit-risk frameworks.
            </p>
            <span class="arca-btn-tertiary" style="display: inline-flex; align-self: flex-start;">
              Watch Recording <span class="arca-arrow">&rarr;</span>
            </span>
          </a>

        </div>

        <div style="text-align: center; margin-top: var(--space-7);">
          <a href="/resource-hub?ta=hematology" class="arca-btn-tertiary">
            View All Hematology Resources <span class="arca-arrow">&rarr;</span>
          </a>
        </div>

      </div>
    </section>

    <!-- SECTION 9: FINAL CTA -->
    <section class="arca-cta-section" data-animate>
      <div style="max-width: 680px; margin: 0 auto; padding: 0 24px;">
        <h2 class="arca-heading-1" style="margin-bottom: var(--space-5);">
          See How ArcaScience Supports Hematology Programs
        </h2>
        <p class="arca-body-lg" style="margin-bottom: var(--space-7);">
          Request a demonstration of ArcaScience's platform configured for hematology benefit-risk analysis. Our scientists will walk through cell/gene therapy safety monitoring capabilities, anticoagulant BRA frameworks, and regulatory output examples relevant to your hematology development program.
        </p>
        <div style="display: flex; gap: 16px; justify-content: center; flex-wrap: wrap;">
          <a href="/contact?ta=hematology" class="arca-btn-primary-inverted">
            Request Hematology Briefing
          </a>
          <a href="/platform-overview" class="arca-btn-secondary" style="border-color: rgba(255,255,255,0.3); color: var(--white);">
            Explore the Platform <span class="arca-arrow">&rarr;</span>
          </a>
        </div>
      </div>
    </section>

  </main>

  <!-- FOOTER -->
  <footer class="arca-bg-blue-900" style="padding: var(--space-9) 0 var(--space-7);">
    <div style="max-width: var(--content-max-width); margin: 0 auto; padding: 0 24px;">
      <div style="display: grid; grid-template-columns: 2fr 1fr 1fr 1fr 1fr; gap: 48px;">

        <!-- Column 1: Brand -->
        <div>
          <img src="/images/arcascience-logo-white.svg" alt="ArcaScience" height="28" style="margin-bottom: var(--space-5);">
          <p class="arca-body-sm" style="color: rgba(255,255,255,0.65); max-width: 280px;">
            AI-driven benefit-risk analysis for pharmaceutical development. Founded 2018.
          </p>
        </div>

        <!-- Column 2: Platform -->
        <div>
          <p class="arca-label" style="color: rgba(255,255,255,0.45); margin-bottom: var(--space-4);">Platform</p>
          <nav style="display: flex; flex-direction: column; gap: 12px;">
            <a href="/platform-overview" style="color: rgba(255,255,255,0.65); text-decoration: none; font-size: 0.875rem;">Overview</a>
            <a href="/platform-data-intelligence" style="color: rgba(255,255,255,0.65); text-decoration: none; font-size: 0.875rem;">Data Intelligence</a>
            <a href="/platform-ai-models" style="color: rgba(255,255,255,0.65); text-decoration: none; font-size: 0.875rem;">Decision Intelligence</a>
            <a href="/platform-outputs" style="color: rgba(255,255,255,0.65); text-decoration: none; font-size: 0.875rem;">Regulatory Outputs</a>
            <a href="/security-compliance" style="color: rgba(255,255,255,0.65); text-decoration: none; font-size: 0.875rem;">Security & Compliance</a>
          </nav>
        </div>

        <!-- Column 3: Solutions -->
        <div>
          <p class="arca-label" style="color: rgba(255,255,255,0.45); margin-bottom: var(--space-4);">Solutions</p>
          <nav style="display: flex; flex-direction: column; gap: 12px;">
            <a href="/solution-early-development" style="color: rgba(255,255,255,0.65); text-decoration: none; font-size: 0.875rem;">Early Development</a>
            <a href="/solution-late-development" style="color: rgba(255,255,255,0.65); text-decoration: none; font-size: 0.875rem;">Late Development</a>
            <a href="/solution-post-marketing" style="color: rgba(255,255,255,0.65); text-decoration: none; font-size: 0.875rem;">Post-Marketing</a>
            <a href="/solution-therapeutic-area" style="color: rgba(255,255,255,0.65); text-decoration: none; font-size: 0.875rem;">Therapeutic Areas</a>
          </nav>
        </div>

        <!-- Column 4: Company -->
        <div>
          <p class="arca-label" style="color: rgba(255,255,255,0.45); margin-bottom: var(--space-4);">Company</p>
          <nav style="display: flex; flex-direction: column; gap: 12px;">
            <a href="/about" style="color: rgba(255,255,255,0.65); text-decoration: none; font-size: 0.875rem;">About</a>
            <a href="/leadership" style="color: rgba(255,255,255,0.65); text-decoration: none; font-size: 0.875rem;">Team</a>
            <a href="/careers" style="color: rgba(255,255,255,0.65); text-decoration: none; font-size: 0.875rem;">Careers</a>
            <a href="/about" style="color: rgba(255,255,255,0.65); text-decoration: none; font-size: 0.875rem;">News</a>
            <a href="/contact" style="color: rgba(255,255,255,0.65); text-decoration: none; font-size: 0.875rem;">Contact</a>
          </nav>
        </div>

        <!-- Column 5: Resources -->
        <div>
          <p class="arca-label" style="color: rgba(255,255,255,0.45); margin-bottom: var(--space-4);">Resources</p>
          <nav style="display: flex; flex-direction: column; gap: 12px;">
            <a href="/evidence-case-studies-hub" style="color: rgba(255,255,255,0.65); text-decoration: none; font-size: 0.875rem;">Case Studies</a>
            <a href="/resources-whitepapers" style="color: rgba(255,255,255,0.65); text-decoration: none; font-size: 0.875rem;">Whitepapers</a>
            <a href="/resources" style="color: rgba(255,255,255,0.65); text-decoration: none; font-size: 0.875rem;">Blog</a>
            <a href="/resources" style="color: rgba(255,255,255,0.65); text-decoration: none; font-size: 0.875rem;">Documentation</a>
          </nav>
        </div>

      </div>

      <!-- Footer bottom -->
      <div style="margin-top: var(--space-8); padding-top: var(--space-5); border-top: 1px solid rgba(255,255,255,0.1); display: flex; justify-content: space-between; align-items: center;">
        <p class="arca-caption" style="color: rgba(255,255,255,0.45);">
          &copy; 2026 ArcaScience. All rights reserved.
        </p>
        <div style="display: flex; gap: 24px;">
          <a href="/legal-privacy" style="color: rgba(255,255,255,0.45); text-decoration: none; font-size: 0.75rem;">Privacy</a>
          <a href="/legal-terms" style="color: rgba(255,255,255,0.45); text-decoration: none; font-size: 0.75rem;">Terms</a>
          <a href="/legal-cookies" style="color: rgba(255,255,255,0.45); text-decoration: none; font-size: 0.75rem;">Cookies</a>
          <a href="/legal-accessibility" style="color: rgba(255,255,255,0.45); text-decoration: none; font-size: 0.75rem;">Accessibility</a>
        </div>
      </div>
    </div>
  </footer>

  <!-- Back to top button -->
  <button data-back-to-top aria-label="Back to top">
    <svg width="16" height="16" viewBox="0 0 16 16" fill="none"><path d="M8 12V4M4 7l4-4 4 4" stroke="currentColor" stroke-width="1.5" stroke-linecap="round"/></svg>
  </button>

  <!-- Global JS -->
  <script src="/dist/arcascience-global.min.js" defer></script>
  <script src="/dist/arcascience-countup.min.js" defer></script>
  <script>
    document.addEventListener('DOMContentLoaded', function() {
      if (window.ArcaScience) ArcaScience.init();
      if (window.ArcaScienceCountUp) ArcaScienceCountUp.init({ selector: '[data-countup]' });

      // Accordion functionality
      document.querySelectorAll('[data-accordion] .arca-accordion-header').forEach(function(header) {
        header.addEventListener('click', function() {
          var content = this.nextElementSibling;
          var icon = this.querySelector('.arca-accordion-icon');
          var isOpen = content.style.display === 'block';

          // Close all accordions in this group
          this.closest('[data-accordion]').querySelectorAll('.arca-accordion-content').forEach(function(c) {
            c.style.display = 'none';
          });
          this.closest('[data-accordion]').querySelectorAll('.arca-accordion-icon').forEach(function(i) {
            i.textContent = '+';
          });

          // Toggle current accordion
          if (!isOpen) {
            content.style.display = 'block';
            icon.textContent = '\u2212';
          }
        });
      });
    });
  </script>

</body>
</html>